Registration Dossier

Administrative data

Endpoint:
acute toxicity: other routes
Type of information:
experimental study
Adequacy of study:
disregarded due to major methodological deficiencies
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Basic data given. However, the study is not relevant for the REACH registration as the route of intravenous administration is not relevant.

Data source

Reference
Reference Type:
publication
Title:
Unnamed
Year:
1985

Materials and methods

Principles of method if other than guideline:
Acute toxicity study with 4 dosages
GLP compliance:
no
Limit test:
no

Test material

Reference
Name:
Unnamed
Type:
Constituent
Test material form:
solid: particulate/powder
Remarks:
migrated information: powder

Test animals

Species:
mouse
Strain:
not specified
Sex:
not specified

Administration / exposure

Route of administration:
intravenous
Doses:
600, 720, 860, 1030 mg/kg bw
No. of animals per sex per dose:
5
Details on study design:
10 days observation period

Results and discussion

Mortality:
LD50 771 mg/kg bw , 95% confidence limits (574.9 - 908.3)

Applicant's summary and conclusion

Conclusions:
LD 50 after intravenous injection to mice: 771 mg/kg bw.
Executive summary:

Dosages of 600, 720, 860 and 1030 mg L-Cysteine monochloride monohydrate/kg bw. were injected intravenously into mice. Afterwords the animals were observed for 10 days.

The LD 50 was 771 mg/kg bw with a 95% confidence interval from 574.9 to 908.3 mg/kg bw..